Developers pursuing new strategies to improve trial efficiency: Tufts CSDD

By Alexandria Pesic

- Last updated on GMT

Related tags Pharmacology

Drug developers are pursuing new strategies to help improve the operational efficiency of their clinical trials, according to a panel of industry leaders recently convened by the Tufts Centre for the Study of Drug Development (CSDD) in Boston, US.

The panel, whose members were drawn exclusively from research-based companies, said they had begun collaborating with investigative sites in developing protocols and educating patients about trials before they agree to participate, in an attempt to streamline the trial process.

“The pharmaceutical and biotech industry is facing a crisis in that it needs to develop new drugs more quickly and control expenses,” ​said Tufts CSDD senior research fellow, Ken Getz.

“Developers understand that substantial operational improvements will more likely flow from new approaches that increase the probability of success, rather than from actions which merely seek to reduce or prevent failures.”

Site failure

According to Tufts CSDD, more than two-thirds of trial sites fail to meet their patient enrolment targets. And, whereas in 2001 nearly half of all screened patients completed trials, in 2010 that figure plummeted to less than one in four.

Getz says some of the blame may lie in the ever increasing number of procedures patients are subjected to, with the median number per trial sky rocketing by 49 per cent between 2000-03 and 2004-07.

“Improving patient enrolment and controlling the number of procedures could provide substantial benefits,” ​he said.

Sponsor communication

The industry leaders convened by Tufts also agreed that communication between sponsors and investigative sites – before, during and after trials – remains critical to the development of good relations.

In addition, medical advisors to help sites better understand trial goals, testing protocols with patients prior to trials, and using electronic medical records to help define and manage data flow, were all agreed by the panel to be of paramount importance to a trial’s success.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more